A recurring question raised by the panel was the
extent to which every breast cancer patient needs to be
included in the model. Disparate viewpoints were raised
about the need for all patients to receive care through prospective
surveillance. Some patients may experience little
or no adverse effects during or after treatment, prompting
the question: Is this model of surveillance necessary for every
patient? Counterpoints were made as to the compelling
data that at each point along the continuum of care
and with each intervention offered, there are potential
physical impairments that might be prevented or mitigated
using the PSM.